Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 3, Multi-center, Prospective, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Effectiveness and Safety of SYM-1219 2 Grams for the Treatment of Women and Post-Menarchal Adolescent Girls With Bacterial Vaginosis

NCT02418845 is registered in ClinicalTrials.gov with Symbiomix Therapeutics as lead sponsor.

NCT NCT02418845
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02418845 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 3, Multi-center, Prospective, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Effectiveness and Safety of SYM-1219 2 Grams for the Treatment of Women and Post-Menarchal Adolescent Girls With Bacterial Vaginosis
Lead sponsor
Symbiomix Therapeutics
Phase
Phase 3
Overall status
Completed
Start date
May 28, 2015
Completion date
December 5, 2015
Enrollment
189 (actual)
Sites
21

Conditions

As the registry lists them; a condition with its own page is linked.

bacterial vaginosis